Initiator Pharma A/S (INIT.ST)
SEK 6.36
(1.92%)
SEK 6.36
(1.92%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -22.87 Thousand DKK | 99.94% |
| 2022 | -38.45 Million DKK | -82.56% |
| 2021 | -21.06 Million DKK | -142.2% |
| 2020 | -8.69 Million DKK | -4.93% |
| 2019 | -8.28 Million DKK | 19.52% |
| 2018 | -10.29 Million DKK | -20.0% |
| 2017 | -8.58 Million DKK | -862.11% |
| 2016 | -892 Thousand DKK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -4.12 Million DKK | -288623.44% |
| 2024 Q2 | -4.78 Million DKK | -16.08% |
| 2023 Q3 | -4.61 Million DKK | 55.73% |
| 2023 Q4 | 1429.00 DKK | 100.03% |
| 2023 FY | -22.87 Thousand DKK | 99.94% |
| 2023 Q1 | -9.26 Million DKK | -213.07% |
| 2023 Q2 | -10.42 Million DKK | -12.46% |
| 2022 Q4 | -2.96 Million DKK | 56.4% |
| 2022 FY | -38.45 Million DKK | -82.56% |
| 2022 Q3 | -6.78 Million DKK | 49.91% |
| 2022 Q2 | -13.55 Million DKK | 10.55% |
| 2022 Q1 | -15.15 Million DKK | -220.07% |
| 2021 Q4 | -4.73 Million DKK | 48.21% |
| 2021 Q3 | -9.14 Million DKK | -69.84% |
| 2021 Q2 | -5.38 Million DKK | -197.84% |
| 2021 FY | -21.06 Million DKK | -142.2% |
| 2021 Q1 | -1.8 Million DKK | -969.23% |
| 2020 Q1 | -2.48 Million DKK | -77.3% |
| 2020 Q2 | -2.99 Million DKK | -20.69% |
| 2020 Q3 | -3.05 Million DKK | -1.97% |
| 2020 FY | -8.69 Million DKK | -4.93% |
| 2020 Q4 | -169 Thousand DKK | 94.47% |
| 2019 Q4 | -1.4 Million DKK | 29.42% |
| 2019 FY | -8.28 Million DKK | 19.52% |
| 2019 Q3 | -1.98 Million DKK | 41.67% |
| 2019 Q2 | -3.4 Million DKK | -127.02% |
| 2019 Q1 | -1.49 Million DKK | -2072.46% |
| 2018 Q3 | -3.63 Million DKK | -10.68% |
| 2018 FY | -10.29 Million DKK | -20.0% |
| 2018 Q4 | -69 Thousand DKK | 98.1% |
| 2018 Q1 | -3.3 Million DKK | -38.98% |
| 2018 Q2 | -3.28 Million DKK | 0.73% |
| 2017 FY | -8.58 Million DKK | -862.11% |
| 2017 Q1 | -1.5 Million DKK | -108.91% |
| 2017 Q3 | -2.51 Million DKK | -14.97% |
| 2017 Q4 | -2.38 Million DKK | 5.21% |
| 2017 Q2 | -2.18 Million DKK | -45.67% |
| 2016 Q4 | -718 Thousand DKK | -337.8% |
| 2016 Q2 | -5000.00 DKK | 0.0% |
| 2016 Q3 | -164 Thousand DKK | -3180.0% |
| 2016 FY | -892 Thousand DKK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Lipum AB (publ) | -37.17 Million SEK | 99.938% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 99.991% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | 99.872% |
| BioArctic AB (publ) | 229.24 Million SEK | 100.01% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | 94.778% |
| Mendus AB (publ) | -101.61 Million SEK | 99.977% |
| Genovis AB (publ.) | 61.5 Million SEK | 100.037% |
| CombiGene AB (publ) | -35.66 Million SEK | 99.936% |
| Intervacc AB (publ) | -102.85 Million SEK | 99.978% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | 99.862% |
| Active Biotech AB (publ) | -45.8 Million SEK | 99.95% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 100.188% |
| Ziccum AB (publ) | -21.41 Million SEK | 99.893% |
| Camurus AB (publ) | 431.44 Million SEK | 100.005% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 99.987% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 99.96% |
| Aptahem AB (publ) | -11.11 Million SEK | 99.794% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 99.993% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 99.987% |
| Kancera AB (publ) | -64.88 Million SEK | 99.965% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 99.981% |
| Fluicell AB (publ) | -26.55 Million SEK | 99.914% |
| Saniona AB (publ) | -95.81 Million SEK | 99.976% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | 99.811% |
| Biovica International AB (publ) | -124.82 Million SEK | 99.982% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 99.946% |
| AcouSort AB (publ) | -17.08 Million SEK | 99.866% |
| Xintela AB (publ) | -54.08 Million SEK | 99.958% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | 99.861% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 99.994% |
| Abliva AB (publ) | -95.5 Million SEK | 99.976% |
| Corline Biomedical AB | -1.8 Million SEK | 98.736% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 100.425% |
| OncoZenge AB (publ) | -15.9 Million SEK | 99.856% |
| Amniotics AB (publ) | -30.87 Million SEK | 99.926% |
| 2cureX AB (publ) | -32.51 Million SEK | 99.93% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 99.993% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | 99.822% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 99.995% |
| Isofol Medical AB (publ) | -37.07 Million SEK | 99.938% |
| I-Tech AB | 20.2 Million SEK | 100.113% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 99.997% |
| Cyxone AB (publ) | -22.98 Million SEK | 99.901% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 99.975% |
| Biosergen AB | -27.03 Million SEK | 99.915% |
| Cantargia AB (publ) | -280.02 Million SEK | 99.992% |
| NextCell Pharma AB | -41.95 Million SEK | 99.945% |
| Nanologica AB (publ) | -75.15 Million SEK | 99.97% |
| SynAct Pharma AB | -215.81 Million SEK | 99.989% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 99.948% |
| LIDDS AB (publ) | -40.2 Million SEK | 99.943% |
| BioInvent International AB (publ) | -330.3 Million SEK | 99.993% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | 99.804% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | 99.904% |
| Alzinova AB (publ) | -16.48 Million SEK | 99.861% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 99.979% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 99.991% |
| Pila Pharma AB (publ) | -9.93 Million SEK | 99.77% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 99.98% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | 99.892% |
| Simris Alg AB (publ) | -37.3 Million SEK | 99.939% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 99.985% |